Monitoring Access to Child Medicines: Introducing a Standardized Set of Age-Appropriate Medicines

Iris R. Joosse,Aukje K. Mantel-Teeuwisse,Fatima Suleman,Hendrika A. van den Ham

DOI: https://doi.org/10.3390/children11030266

2024-02-20

Children

Abstract:Monitoring access to pediatric medicines as part of the Sustainable Development Goal (SDG) agenda for 2030 requires surveying age-appropriate medicines. This study aimed to develop tracer sets of essential age-appropriate medicines for use in SDG indicator 3.b.3 or in conjunction with other methodologies for monitoring access to medicines. Two sets of medicines were developed, one for young children (1 month to 5 years) and one for school-aged children (5–12 years). Priority diseases were selected based on the global burden of disease and linked to active ingredients of first choice according to treatment guidelines and the World Health Organization (WHO) Model List of Essential Medicines for Children (EMLc). To ensure clinical relevance, the Delphi technique was employed to identify areas of (dis)agreement among clinical pediatric experts. During two consultation rounds, experts were invited to indicate (dis)agreement. Five experts per age group were largely in agreement with the initial selections, but various therapeutic alternatives were suggested for addition. A second consultation round with five experts did not lead to major adjustments. The final sets included 26 treatment options for both groups. Specific age-appropriate formulations were selected from the WHO EMLc 2023. These two globally representative tracer sets of medicines consider the particular needs of children and could aid countries in the critical monitoring of accessibility to pediatric medicines.

pediatrics

What problem does this paper attempt to address?

The problem this paper attempts to address is the monitoring of pediatric drug accessibility. Specifically, the goal of the paper is to develop a standardized core list of medicines for monitoring the accessibility of essential medicines for children of different age groups. These medicine lists will be used to support the monitoring of Sustainable Development Goal (SDG) indicator 3.b.3, which aims to measure the availability and affordability of essential medicines in basic health facilities.

The paper points out that existing SDG indicators have limitations when applied to pediatric medicines, as these indicators are primarily based on adult medication regimens and lack appropriate formulations for children. Therefore, the research team developed two sets of medicine lists, targeting children aged 1 month to 5 years and 5 to 12 years, respectively, to ensure that the medicines meet the needs of children in different age groups. Through this approach, it is possible to better assess and improve the accessibility of pediatric medicines globally.